title: Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Metz
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Schütz
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Karsten
authors.initials: K
authors.lastname: Weller
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Marina
authors.initials: M
authors.lastname: Gorczyza
authors.affiliation: Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Zimmer
authors.affiliation: Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Staubach
authors.affiliation: Department of Dermatology and Allergy, RWTH Aachen University, Aachen, Germany.
authors.forename: Hans F
authors.initials: HF
authors.lastname: Merk
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: marcus.maurer@charite.de.
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D003080:Cold Temperature / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000209:etiology
chemical_list: D018926:Anti-Allergic Agents; D000069444:Omalizumab